By Benjamin Chiou
Date: Thursday 30 Apr 2026
(Sharecast News) - Merck & Co beat market forecasts with its first-quarter results on Thursday and raised its full-year guidance on the back of strong growth for Keytruda, its flagship humanised monoclonal antibody (PD-1 inhibitor) used to treat 18 types of cancer.
No recent information was found.
| Currency | US Dollars |
| Share Price | $ 111.38 |
| Change Today | $ -0.92 |
| % Change | -0.82 % |
| 52 Week High | $123.18 |
| 52 Week Low | $73.47 |
| Volume | 5,725,143 |
| Shares Issued | 2,474.63m |
| Market Cap | $275,624m |
| RiskGrade | 92 |
| Strong Buy | 8 |
| Buy | 10 |
| Neutral | 10 |
| Sell | 0 |
| Strong Sell | 0 |
| Total | 28 |

| Time | Volume / Share Price |
| 16:00 | 1,285,554 @ $111.38 |
| 16:00 | 457 @ $111.36 |
| 16:00 | 200 @ $111.36 |
| 16:00 | 1,440 @ $111.37 |
| 16:00 | 100 @ $111.38 |
You are here: research